Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences

Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital…

Paul Sekhri Joins Topas Therapeutics as Chairman of the Board

Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately. Paul Sekhri is currently CEO and President of the US…

Caldan Therapeutics Announces Key Appointment

Edinburgh, United Kingdom, February 27, 2017 – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH),…